Tweet
Lexicon Pharmaceuticals (NASDAQ:LXRX) was downgraded by equities research analysts at BidaskClub from a "hold" rating to a "sell" rating in a research note issued on Friday.
LXRX has been the subject of several other research reports. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 26th. Stifel Nicolaus reaffirmed a "buy" rating and issued a $23.00 price objective (down previously from $24.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, July 31st. Citigroup lowered their price objective on shares of Lexicon Pharmaceuticals from $28.00 to $27.00 and set a "buy" rating for the company in a research report on Friday, May 4th. ValuEngine raised shares of Lexicon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Friday, June 1st. Finally, Needham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Monday, July 30th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company's stock. The company currently has a consensus rating of "Hold" and an average price target of $24.60. Get Lexicon Pharmaceuticals alerts:
Shares of NASDAQ:LXRX opened at $10.45 on Friday. The company has a debt-to-equity ratio of -45.80, a current ratio of 2.71 and a quick ratio of 2.68. Lexicon Pharmaceuticals has a 52-week low of $7.67 and a 52-week high of $15.16. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -8.23 and a beta of 0.33. Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Monday, July 30th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.35) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 137.32% and a negative return on equity of 369.13%. The company had revenue of $13.75 million during the quarter, compared to the consensus estimate of $15.88 million. During the same quarter last year, the company earned ($0.33) earnings per share. Lexicon Pharmaceuticals's revenue for the quarter was up 14.1% on a year-over-year basis. analysts anticipate that Lexicon Pharmaceuticals will post -1.38 EPS for the current fiscal year.
In other news, VP James F. Tessmer sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $12.91, for a total transaction of $129,100.00. Following the completion of the sale, the vice president now owns 35,643 shares of the company's stock, valued at $460,151.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . Also, Director Public Equities L.P. Invus purchased 138,700 shares of the firm's stock in a transaction dated Friday, May 25th. The shares were bought at an average cost of $9.62 per share, with a total value of $1,334,294.00. The disclosure for this purchase can be found here . Insiders have bought 1,924,615 shares of company stock valued at $22,552,542 in the last three months. Corporate insiders own 6.10% of the company's stock.
Hedge funds have recently added to or reduced their stakes in the company. Two Sigma Advisers LP bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth $104,000. Quantitative Systematic Strategies LLC lifted its stake in Lexicon Pharmaceuticals by 61.4% during the first quarter. Quantitative Systematic Strategies LLC now owns 19,171 shares of the biopharmaceutical company's stock worth $164,000 after purchasing an additional 7,296 shares during the last quarter. Tocqueville Asset Management L.P. bought a new position in Lexicon Pharmaceuticals during the second quarter worth $164,000. Aperio Group LLC lifted its stake in Lexicon Pharmaceuticals by 49.5% during the first quarter. Aperio Group LLC now owns 19,270 shares of the biopharmaceutical company's stock worth $165,000 after purchasing an additional 6,377 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in Lexicon Pharmaceuticals during the first quarter worth $177,000.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults